Table 3.
Open in new tab

Exposure to Treatment and Adherence to Treatment

a) Main period
SomapacitanDaily GHPlacebo
(N = 120)(N = 119)(N = 61)
Exposure to treatment, days
 Mean232 (36.2)226 (48.0)228 (36.1)
 Median238238238
Treatment dose, mg, mean (SD)2.56 (1.48) mg/week Equivalent to 0.37 mg/day0.33 (0.19) mg/day Equivalent to 2.31 mg/week2.20 (0.74) mg/week Equivalent to 0.31 mg/day
Mean adherence, %95.590.693.9
b) Extension period
Somapacitan/ SomapacitanDaily GH/ Daily GHPlacebo/ SomapacitanDaily GH/ Somapacitan
(N = 114)(N = 52)(N = 55)(N = 51)
Exposure to treatment, days
 Mean355 (52.4)349 (48.8)357 (40.4)343 (76.6)
 Median364364364364
Treatment dose in extension, mg, mean (SD)2.35 (1.30) mg/week Equivalent to 0.34 mg/day0.28 (0.16) mg/day Equivalent to 1.96 mg/week2.61 (1.40) mg/week Equivalent to 0.37 mg/day2.66 (1.37) mg/week Equivalent to 0.38 mg/day
Mean adherence during extension, %94.791.989.894.7
a) Main period
SomapacitanDaily GHPlacebo
(N = 120)(N = 119)(N = 61)
Exposure to treatment, days
 Mean232 (36.2)226 (48.0)228 (36.1)
 Median238238238
Treatment dose, mg, mean (SD)2.56 (1.48) mg/week Equivalent to 0.37 mg/day0.33 (0.19) mg/day Equivalent to 2.31 mg/week2.20 (0.74) mg/week Equivalent to 0.31 mg/day
Mean adherence, %95.590.693.9
b) Extension period
Somapacitan/ SomapacitanDaily GH/ Daily GHPlacebo/ SomapacitanDaily GH/ Somapacitan
(N = 114)(N = 52)(N = 55)(N = 51)
Exposure to treatment, days
 Mean355 (52.4)349 (48.8)357 (40.4)343 (76.6)
 Median364364364364
Treatment dose in extension, mg, mean (SD)2.35 (1.30) mg/week Equivalent to 0.34 mg/day0.28 (0.16) mg/day Equivalent to 1.96 mg/week2.61 (1.40) mg/week Equivalent to 0.37 mg/day2.66 (1.37) mg/week Equivalent to 0.38 mg/day
Mean adherence during extension, %94.791.989.894.7
Table 3.
Open in new tab

Exposure to Treatment and Adherence to Treatment

a) Main period
SomapacitanDaily GHPlacebo
(N = 120)(N = 119)(N = 61)
Exposure to treatment, days
 Mean232 (36.2)226 (48.0)228 (36.1)
 Median238238238
Treatment dose, mg, mean (SD)2.56 (1.48) mg/week Equivalent to 0.37 mg/day0.33 (0.19) mg/day Equivalent to 2.31 mg/week2.20 (0.74) mg/week Equivalent to 0.31 mg/day
Mean adherence, %95.590.693.9
b) Extension period
Somapacitan/ SomapacitanDaily GH/ Daily GHPlacebo/ SomapacitanDaily GH/ Somapacitan
(N = 114)(N = 52)(N = 55)(N = 51)
Exposure to treatment, days
 Mean355 (52.4)349 (48.8)357 (40.4)343 (76.6)
 Median364364364364
Treatment dose in extension, mg, mean (SD)2.35 (1.30) mg/week Equivalent to 0.34 mg/day0.28 (0.16) mg/day Equivalent to 1.96 mg/week2.61 (1.40) mg/week Equivalent to 0.37 mg/day2.66 (1.37) mg/week Equivalent to 0.38 mg/day
Mean adherence during extension, %94.791.989.894.7
a) Main period
SomapacitanDaily GHPlacebo
(N = 120)(N = 119)(N = 61)
Exposure to treatment, days
 Mean232 (36.2)226 (48.0)228 (36.1)
 Median238238238
Treatment dose, mg, mean (SD)2.56 (1.48) mg/week Equivalent to 0.37 mg/day0.33 (0.19) mg/day Equivalent to 2.31 mg/week2.20 (0.74) mg/week Equivalent to 0.31 mg/day
Mean adherence, %95.590.693.9
b) Extension period
Somapacitan/ SomapacitanDaily GH/ Daily GHPlacebo/ SomapacitanDaily GH/ Somapacitan
(N = 114)(N = 52)(N = 55)(N = 51)
Exposure to treatment, days
 Mean355 (52.4)349 (48.8)357 (40.4)343 (76.6)
 Median364364364364
Treatment dose in extension, mg, mean (SD)2.35 (1.30) mg/week Equivalent to 0.34 mg/day0.28 (0.16) mg/day Equivalent to 1.96 mg/week2.61 (1.40) mg/week Equivalent to 0.37 mg/day2.66 (1.37) mg/week Equivalent to 0.38 mg/day
Mean adherence during extension, %94.791.989.894.7
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close